Lidamycin (an enediyne anticancer antibiotic) was able to reduce tumor initiating cells of hepatocellular carcinoma reducing stem cell markers expression, such as EpCAM, by inhibiting Wnt/β-catenin pathway activation. The gene discussed is EPCAM; the disease is hepatocellular carcinoma.